Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 1 |
2022 | 2 |
2023 | 2 |
2024 | 2 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
krzysztof milewski
(141 results)?
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy.
Mol Cancer Ther. 2023 Jul 5;22(7):807-817. doi: 10.1158/1535-7163.MCT-22-0721.
Mol Cancer Ther. 2023.
PMID: 36939275
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I-Indole Derivatives.
Stypik M, Zagozda M, Michałek S, Dymek B, Zdżalik-Bielecka D, Dziachan M, Orłowska N, Gunerka P, Turowski P, Hucz-Kalitowska J, Stańczak A, Stańczak P, Mulewski K, Smuga D, Stefaniak F, Gurba-Bryśkiewicz L, Leniak A, Ochal Z, Mach M, Dzwonek K, Lamparska-Przybysz M, Dubiel K, Wieczorek M.
Stypik M, et al. Among authors: mulewski k.
Pharmaceuticals (Basel). 2022 Jul 30;15(8):949. doi: 10.3390/ph15080949.
Pharmaceuticals (Basel). 2022.
PMID: 36015098
Free PMC article.
Item in Clipboard
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II-Benzimidazole Derivatives.
Stypik M, Michałek S, Orłowska N, Zagozda M, Dziachan M, Banach M, Turowski P, Gunerka P, Zdżalik-Bielecka D, Stańczak A, Kędzierska U, Mulewski K, Smuga D, Maruszak W, Gurba-Bryśkiewicz L, Leniak A, Pietruś W, Ochal Z, Mach M, Zygmunt B, Pieczykolan J, Dubiel K, Wieczorek M.
Stypik M, et al. Among authors: mulewski k.
Pharmaceuticals (Basel). 2022 Jul 27;15(8):927. doi: 10.3390/ph15080927.
Pharmaceuticals (Basel). 2022.
PMID: 36015075
Free PMC article.
Item in Clipboard
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma.
Gunerka P, Gala K, Banach M, Dominowski J, Hucz-Kalitowska J, Mulewski K, Hajnal A, Mikus EG, Smuga D, Zagozda M, Dubiel K, Pieczykolan J, Zygmunt BM, Wieczorek M.
Gunerka P, et al. Among authors: mulewski k.
PLoS One. 2020 Jul 23;15(7):e0236159. doi: 10.1371/journal.pone.0236159. eCollection 2020.
PLoS One. 2020.
PMID: 32702053
Free PMC article.
Item in Clipboard
Structure-Based Discovery of High-Affinity Small Molecule Ligands and Development of Tool Probes to Study the Role of Chitinase-3-Like Protein 1.
Czestkowski W, Krzemiński Ł, Piotrowicz MC, Mazur M, Pluta E, Andryianau G, Koralewski R, Matyszewski K, Olejniczak S, Kowalski M, Lisiecka K, Kozieł R, Piwowar K, Papiernik D, Nowotny M, Napiórkowska-Gromadzka A, Nowak E, Niedziałek D, Wieczorek G, Siwińska A, Rejczak T, Jędrzejczak K, Mulewski K, Olczak J, Zasłona Z, Gołębiowski A, Drzewicka K, Bartoszewicz A.
Czestkowski W, et al. Among authors: mulewski k.
J Med Chem. 2024 Mar 14;67(5):3959-3985. doi: 10.1021/acs.jmedchem.3c02255. Epub 2024 Mar 1.
J Med Chem. 2024.
PMID: 38427954
Item in Clipboard
Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists.
Pankiewicz P, Szybiński M, Kisielewska K, Gołębiowski F, Krzemiński P, Rutkowska-Włodarczyk I, Moszczyński-Pętkowski R, Gurba-Bryśkiewicz L, Delis M, Mulewski K, Smuga D, Dominowski J, Janusz A, Górka M, Abramski K, Napiórkowska A, Nowotny M, Dubiel K, Kalita K, Wieczorek M, Pieczykolan J, Matłoka M.
Pankiewicz P, et al. Among authors: mulewski k.
Pharmaceuticals (Basel). 2021 Jul 21;14(8):704. doi: 10.3390/ph14080704.
Pharmaceuticals (Basel). 2021.
PMID: 34451801
Free PMC article.
Item in Clipboard
Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.
Popiel D, Stańczak A, Skupińska M, Mikołajczyk A, Stańczak P, Mituła F, Hucz-Kalitowska J, Jastrzębska K, Smuga D, Dominowski J, Delis M, Mulewski K, Pietruś W, Zdżalik-Bielecka D, Dzwonek K, Lamparska-Przybysz M, Yamani A, Olejkowska P, Piórkowska N, Dubiel K, Wieczorek M, Pieczykolan J.
Popiel D, et al. Among authors: mulewski k.
Front Oncol. 2024 Jan 12;13:1293728. doi: 10.3389/fonc.2023.1293728. eCollection 2023.
Front Oncol. 2024.
PMID: 38282676
Free PMC article.
Item in Clipboard
Cite
Cite